Investor Ideas #Potcasts
599, #Cannabis News and #Stocks on the Move; (NASDAQ: $HUGE) (CSE: $HUGE.C),
(TSX: $FAF.TO) (TSXV: $BEER.V) (TSX: $TGOD.TO) (OTC: $TGODF)
Delta, Kelowna, BC, August 26, 2021 (Investorideas.com Newswire)
www.Investoride, as.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast
edition of cannabis news and
stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/082621-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/08261HUGE-FAF-BEER-TGOD.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
The
Green Organic Dutchman Holdings Ltd. (TSX:
TGOD) (OTC:
TGODF), a leading producer of premium certified organically
grown cannabis, announced that it
completed its first international commercial shipment consisting of cannabis
flower and other extracts destined for the highly anticipated South African
medical cannabis market.
TGOD's cannabis flower will be the
first to be distributed legally in the country at a commercial scale. Its
products received the approval of the South African Health Products Regulatory
Authority (SAHPRA). This illustrates the value of TGOD's organic portfolio and
bolsters its position in securing international market access. TGOD continues to see demand and
opportunities for superior quality, high potency, and consistent products,
which the CleanCraft™ processes enable TGOD to deliver.
"This is an important milestone
in our strategy to export our certified organically grown medical cannabis
products to international markets. We are confident that our in-country partner
will continue to develop this nascent market and that TGOD's portfolio of
products will be well received by patients that have previously lacked access
to legal, high-quality medical cannabis " commented Sean Bovingdon, TGOD's
CEO and Interim CFO. "We are pleased to be able to complete our first
shipment mid-Q3 2021, in line with our corporate objectives. This is setting the base for our large-scale
commercialisation into the international market in 2022," added Bovingdon.
Hill
Street Beverage Company Inc. (TSXV:
BEER) announced that
its California licensee - Trinidad Consulting LLC, has started production in
preparation to launch a new THC infused line of its top-selling Cannadips
products. Powered by DehydraTECH™ fast-acting technology through a licensing
agreement with Hill Avenue Cannabis, this latest innovation follows the
extremely successful use of DehydraTECH™ technology in their national CBD
product lineup.
Based in Humboldt County,
California, Cannadips is the leading brand of smokeless nicotine and tobacco
free dips in the United States. The company currently manufactures and
distributes their popular CBD brand through exclusive licensee, Boldt Runners
Corporation, in over 5,500 stores across the US. The modern oral pouch category
is growing exponentially in the US, representing a $7 billion market category
comprised of 6.5 million smokeless tobacco users. With the launch of the new
THC line, Cannadips continues to lead innovation in the category, further
pioneering the modern dip alternative.
"We're delighted that this
latest Cannadips innovation is powered by DehydraTECH™," said Craig
Binkley, Co-CEO of Hill Street. "Our mission is to partner with brands
that are driven to deliver premium quality and category leading performance.
Cannadips aligns perfectly with these values as they constantly pursue the
highest craft quality combined with the most advanced technology to ensure that
consumers enjoy a superior experience. Cannadips has already proven that
DehydraTECH™ technology is superior through their highly successful CBD product
lineup."
Patented DehydraTECH™ technology
improves the way active pharmaceutical ingredients (APIs) enter the
bloodstream, delivering advantages such as faster onset and more predictable
cannabis experiences for consumers.
"Delivering best in category
value propositions is of utmost importance to us," said Case Mandel,
co-founder of Cannadips. "In our quest to create the ultimate smokeless,
oral cannabinoid experience for our customers, we found that DehydraTECH™ is
the perfect technology for our products and is hands-down the highest
performing technology we have tried. It preserves the valuable terpenes found
in our cannabis extracts and increases cannabinoid bioavailability, allowing
for quick absorption directly in the mouth."
The moment is right for launching
Cannadips THC, as the Cannadips brand has strong awareness with CBD/hemp
consumers which will provide a halo effect when it arrives in California
dispensaries statewide. Cannadips has developed strong partnerships that will
allow both speed to market and best in class sales and distribution. Their
manufacturing partner ArcataX Inc provides best in class manufacturing and an
exclusive distribution deal with Herbl, the largest cannabis supply chain
company in California, will be key drivers of success at retail.
"At Hill Street we have a
strong conviction to work with brands that matter. We believe in the power of
cannabis and best in class science to create product alternatives that are both
better and better for you", said Lori Senecal, Co-CEO of Hill Street.
"The Cannadips products are a shining example of this commitment. They
offer adult consumers a high quality product and a better alternative to
tobacco and nicotine with CBD and now THC infused options. We're delighted
that, with this launch, California becomes the next state where DehydraTECH™
THC will be active in the market."
The Cannadips THC line will
initially be available in two strengths. The mega-dose cans will have 500mg of
THC resulting in 25mg per pouch and the daily dose offering will contain 150mg
of THC per can, or 10mg per pouch. The new line-up is anticipated to make its
debut at the Hall of Flowers in late September and become available for
pre-order before rolling out statewide in California in October 2021.
Fire
& Flower Holdings Corp. (TSX:
FAF)
(OTCQX:
FFLWF) and its wholly-owned subsidiary Hifyre™ Inc., today
announced the proposed acquisition of all issued and
outstanding shares of PGED Corp., ("PotGuide"),
one of the world's largest cannabis websites and content platforms.
PotGuide is one of the most visited
cannabis websites in North America, as reported by industry-standard online
traffic tools. Along with the proposed acquisition of certain assets of Wikileaf
Technologies Inc. announced earlier this month, the Hifyre digital network will
become one of the world's most visited networks of cannabis websites and
content platforms.
Upon closing, the Acquisition is
expected to be immediately accretive to the Company's revenue and profitability
and will provide Hifyre with a U.S. base for technology and operations.
Following closing of the
Acquisition, Hifyre intends to leverage this significant user traffic and its
proprietary white-label dispensary e-commerce software to convert traffic into
cannabis and accessory purchases. The purchases will be fulfilled by the Fire
& Flower retail network across Canada and in California through its
agreement with Fire & Flower U.S. Holdings Inc. Hifyre anticipates creating
additional agreements with dispensary networks across Canada and the U.S. to
fulfill cannabis purchases in as many geographic locations as possible.
PotGuide and Wikileaf bring an
existing subscriber base of approximately 225,000 cannabis consumers into the
Spark Perks™ ecosystem. Subscribers will be invited to enroll in the Company's
Spark Perks™ member program, which already boasts over 300,000 subscribers. The
program allows members to unlock unique benefits and helps Hifyre build a
greater understanding of cannabis consumer preferences across North America as
part of the Hifyre IQ data program.
"As Fire & Flower has grown
over the past few years, we have successfully proven the value of our Hifyre
data analytics retail platform and it is a great accomplishment to see the
rapid success of our expanding digital strategy with the acquisition of
PotGuide," shared Trevor Fencott, Chief Executive Officer of Fire &
Flower. "Now that we are strategically acquiring two of the most visited
cannabis online websites, PotGuide and Wikileaf, we have established Fire &
Flower and Hifyre as leading global players in digital cannabis traffic and
believe we can offer even greater value to these high-demand properties."
"PotGuide is excited to join
the Fire & Flower and Hifyre network of properties and we look forward to
continuing to build one of the leading North American cannabis technology
companies," shared Jeremy Bamford, Chief Executive Officer of PGED Corp.
"The ability to leverage the significant web traffic of PotGuide.com with
Hifyre's cannabis e-commerce technology will enable us to offer an increased
value proposition to our users and enhance the growth strategy of our
business."
FSD Pharma Inc. (NASDAQ:
HUGE) (CSE:
HUGE), a life sciences holding company dedicated to
building a portfolio of assets and biotech solutions in legal psychedelics and
medical cannabis, announced that it
has entered a definitive agreement to acquire 100% of the issued and outstanding
shares Lucid Psycheceuticals Inc., a Canadian-based specialty psychedelic
pharmaceutical company focused on the development of therapies to treat
critical neurodegenerative diseases, for approximately US$9 million (CAD$11.3
million) in FSD Pharma stock (the "Transaction"), as further
described below.
"The
acquisition of a distinctive company like Lucid illustrates FSD Pharma’s vision
to build a portfolio of biotechnology assets on a new frontier of medicine that
hold the potential to treat mental health disorders and neurodegenerative
diseases in a new way," said Anthony Durkacz, Interim CEO of FSD Pharma.
"Lucid has successfully developed a strong pipeline of novel therapeutic
compounds — supported by IP in order to advance to future clinical trials — and
we are confident that the experience the Lucid leadership team brings will
allow us to immediately start the process towards clinical trials to further
advance these promising therapies. This is an exciting venture for FSD Pharma
that we believe represents a paradigm shift in the development and outlook of
our company."
Founded
in 2020, Lucid is developing novel molecules and combinations with the goal of
addressing Total Brain Health and targeting some of the most challenging
neurodegenerative diseases, such as Multiple sclerosis, and other Brain
conditions. Lucid has exclusive worldwide licensing rights from the University
Health Network, North America’s largest health research organization, to a
patent-protected family of new chemical entities (NCEs), on which Lucid’s
development platform is based and from which its lead neurodegenerative
disorders therapeutic candidate, Lucid-21-302, has been derived. In addition,
Lucid’s pipeline includes Lucid-201, a psychedelic drug candidate targeting mental
health disorders, and it is also investigating certain cannabinoids.
In
addition, upon closing of the transaction Lucid’s co-founder and CEO, Dr.
Lakshmi Kotra will be transitioning to the FSD Pharma team with Prof. Kotra
taking on the role of leading the development of FSD Pharma’s drug development
pipeline in Psychedelics and Medical Cannabis. Dr. Kotra is a Professor of
Medicinal Chemistry at the University of Toronto, and senior scientist at
Krembil Brain Institute at the University Health Network.
Prof.
Lakshmi Kotra, co-founder and CEO of Lucid, commented, "We started with a
vision to accelerate therapies for Total Brain Health. Since inception, we have
made significant progress and built a strong scientific and execution team. We
are excited to enter a new phase of growth with FSD Pharma. I am personally
delighted with FSD Pharma leadership’s shared commitment to bring forward
advanced therapeutics addressing challenging health issues. We believe our
combined resources and experienced teams will position us to enter clinical
development programs to deliver highly effective therapeutic products in
neurodegenerative disorders and mental health areas."
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts
visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also
available on iTunes ( Apple Podcasts) ,
Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms
available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big
Investing Ideas
Investorideas.com
publishes breaking stock news, third
party stock research , guest posts and original
articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and
IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor
Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play
sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast , Cleantech and Climate
Change , Exploring Mining , Betting on Gaming Stocks
Podcast and the AI Eye
Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact
management and IR of each company directly regarding specific questions. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile
App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment